| Literature DB >> 21324209 |
Kazuki Harada1, Erika Morimoto, Yasushi Kataoka, Toshio Takahashi.
Abstract
Although the dog breeding industry is common in many countries, the presence of antimicrobial resistant bacteria among pups in kennels has been infrequently investigated. This study was conducted to better understand the epidemiology of antimicrobial-resistant Escherichia coli isolates from kennel pups not treated with antimicrobials. We investigated susceptibilities to 11 antimicrobials, and prevalence of extended-spectrum β-lactamase (ESBL) in 86 faecal E. coli isolates from 43 pups in two kennels. Genetic relatedness among all isolates was assessed using pulsed-field gel electrophoresis (PFGE). Susceptibility tests revealed that 76% of the isolates were resistant to one or more of tested antimicrobials, with resistance to dihydrostreptomycin most frequently encountered (66.3%) followed by ampicillin (60.5%), trimethoprim-sulfamethoxazole (41.9%), oxytetracycline (26.7%), and chloramphenicol (26.7%). Multidrug resistance, defined as resistance against two or more classes of antimicrobials, was observed in 52 (60.5%) isolates. Three pups in one kennel harboured SHV-12 ESBL-producing isolates. A comparison between the two kennels showed that frequencies of resistance against seven antimicrobials and the variation in resistant phenotypes differed significantly. Analysis by PFGE revealed that clone sharing rates among pups of the same litters were not significantly different in both kennels (64.0% vs. 88.9%), whereas the rates among pups from different litters were significantly different between the two kennels (72.0% vs. 33.3%, P < 0.05). The pups in the two kennels had antimicrobial-resistant E. coli clones, including multidrug-resistant and ESBL-producing clones. It is likely that resistant and susceptible bacteria can clonally spread among the same and/or different litters thus affecting the resistance prevalence.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21324209 PMCID: PMC3047438 DOI: 10.1186/1751-0147-53-11
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Details of surveyed pups in this study.
| Kennel | Litter | Breed | No. of pups | Pup identity | Date of birth | Age in days |
|---|---|---|---|---|---|---|
| A | A-a | Toy poodle | 3 | A-a-1 - A-a-3 | 5/13/2009 | 30 |
| A-b | Toy poodle | 3 | A-b-1 - A-b-3 | 5/15/2009 | 28 | |
| A-c | Chihuahua | 2 | A-c-1 - A-c-2 | 4/17/2009 | 57 | |
| A-d | Toy poodle | 3 | A-d-1 - A-d-3 | 6/23/2009 | 45 | |
| A-e | Toy poodle | 4 | A-e-1 - A-e-4 | 7/1/2009 | 37 | |
| A-f | Toy poodle | 5 | A-f-1 - A-f-5 | 7/9/2009 | 29 | |
| A-g | Toy poodle | 3 | A-g-1-A-g-3 | 9/2/2009 | 38 | |
| A-h | Toy poodle | 2 | A-h-1 - A-h-2 | 9/6/2009 | 35 | |
| Total | 25 | |||||
| B | B-a | Maltese | 2 | B-a-1 - B-a-2 | 8/3/2009 | 46 |
| B-b | Beagle | 4 | B-b-1 - B-b-4 | 7/29/2009 | 51 | |
| B-c | Miniature dachshund | 5 | B-c-1 - B-c-5 | 8/1/2009 | 51 | |
| B-d | Papillon | 3 | B-d-1 - B-d-3 | 8/17/2009 | 53 | |
| B-e | Chihuahua | 4 | B-e-1 - B-e-4 | 8/25/2009 | 55 | |
| Total | 18 | |||||
The minimum inhibitory concentration (MIC) range and resistance rates among Escherichia coli isolates from pups originating from two kennels (A and B).
| MIC range (μg/mL) | No. of resistant isolates (%)/No. of pups that harboured resistant isolate(s) (%) | ||||||
|---|---|---|---|---|---|---|---|
| Total | Kennel A | Kennel B | |||||
| (n = 86/43) | (n = 50/25) | (n = 36/18) | |||||
| AMP | 2 - >512 | >512 | >512 | ≥32 | 52 (60.5)/30 (69.8) | 29 (58.0)/17 (68.0) | 23 (63.9)/13 (72.2) |
| CFZ | 8 - 128 | 4 | 8 | ≥32 | 5 (5.8)/3 (7.0) | 0 (0)/0 (0) | 5 (13.9)*/3 (16.7) |
| CEF | ≤0.125 - 32 | 0.5 | 1 | ≥8 | 5 (5.8)/3 (7.0) | 0 (0)/0 (0) | 5 (13.9)*/3 (16.7) |
| DHS | 2 - >512 | 512 | >512 | ≥32 | 57 (66.3)/32 (74.4) | 35 (70.0)/19 (76.0) | 22 (61.1)/13 (72.2) |
| GEN | 0.5 - 256 | 1 | 128 | ≥16 | 16 (18.6)/12 (27.9) | 16 (32.0)*/12 (48.0)* | 0 (0)/0 (0) |
| KAN | 2 - >512 | 4 | 16 | ≥64 | 3 (3.5)/2 (4.7) | 3 (6.0)/2 (8.0) | 0 (0)/0 (0) |
| OTC | 1 - 512 | 2 | 512 | ≥16 | 23 (26.7)/17 (39.5) | 18 (36.0)*/14 (56.0)* | 5 (13.9)/3 (16.7) |
| CHL | 4 - >512 | 8 | 512 | ≥32 | 23 (26.7)/17 (39.5) | 18 (36.0)*/14 (56.0)* | 5 (13.9)/3 (16.7) |
| NAL | 2 - >512 | 4 | 16 | ≥32 | 7 (8.1)/5 (11.6) | 2 (4.0)/2 (8.0) | 5 (13.9)/3 (16.7) |
| ENR | ≤0.03 - 256 | 0.06 | 1 | ≥4 | 5 (5.8)/3 (7.0) | 0 (0)/0 (0) | 5 (13.9)*/3 (16.7) |
| SXT | ≤0.25/4.75 - >64/1216 | 1/19 | >64/1216 | ≥16/304 | 36 (41.9)/21 (48.8) | 27 (54.0)*/16 (64.0)* | 9 (25.0)/5 (27.8) |
aAMP, ampicillin; CFZ, cefazolin; CEF, ceftiofur; DHS, dihydrostreptomycin; GEN, gentamicin; KAN, kanamycin; OTC, oxytetracycline; CHL, chloramphenicol; NAL, nalidixic acid; ENR, enrofloxacin; SXT, trimethoprim-sulfamethoxazole.
bThe breakpoints for AMP, CFZ, CEF, GEN, KAN, OTC, CHL, ENR and SXT, and that for NAL were based on CLSI document M31-A3 [9] and M100-S20 [8], respectively, whereas the breakpoint of DHS was based on an epidemiological cut-off value according to another report [10]
The distribution of resistance phenotypes among Escherichiacoli isolates from pups in two kennels (A and B).
| No. of resistant isolates (%)/No. of pups that harboured resistant isolate (s) (%) | |||
|---|---|---|---|
| Total | Kennel A | Kennel B | |
| (n = 86/43) | (n = 50/25) | (n = 36/18) | |
| AMP-CFZ-CFT-OTC-CHL-NAL-ENR | 5 (5.8)/3 (7.0) | 0 (0)/0 (0) | 5 (13.9)/3 (16.7) |
| AMP-DHS-GEN-KAN-OTC-CHL-SXT | 3 (3.5)/2 (4.7) | 3 (6.0)/2 (8.0) | 0 (0)/0 (0) |
| AMP-DHS-GEN-OTC-CHL-NAL-SXT | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| AMP-DHS-GEN-OTC-CHL-SXT | 11 (12.8)/9 (20.9) | 11 (22.0)/9 (36.0) | 0 (0)/0 (0) |
| AMP-DHS-GEN-CHL-SXT | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| AMP-DHS-OTC-SXT | 2 (2.3)/1 (2.3) | 2 (4.0)/1 (4.0) | 0 (0)/0 (0) |
| AMP-DHS-CHL-SXT | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| AMP-DHS-SXT | 16 (18.6)/13 (30.2) | 8 (16.0)/8 (32.0) | 8 (22.2)/5 (27.8) |
| AMP-DHS-CHL | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| AMP-DHS | 10 (11.6)/6 (14.0) | 0 (0)/0 (0) | 10 (27.8)/6 (33.3) |
| DHS-SXT | 1 (1.2)/1 (2.3) | 0 (0)/0 (0) | 1 (2.8)/1 (5.6) |
| AMP | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| DHS | 10 (11.6)/7 (16.3) | 7 (14.0)/5 (20.0) | 3 (8.3)/2 (11.1) |
| OTC | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| NAL | 1 (1.2)/1 (2.3) | 1 (2.0)/1 (4.0) | 0 (0)/0 (0) |
| Susceptible | 21 (24.4)/13 (30.2) | 12 (24.0)/7 (28.0) | 9 (25.0)/6 (33.3) |
aAMP, ampicillin; CFZ, cefazolin; CEF, ceftiofur; DHS, dihydrostreptomycin; GEN, gentamicin; KAN, kanamycin; OTC, oxytetracycline; CHL, chloramphenicol; NAL, nalidixic acid; ENR, enrofloxacin; SXT, trimethoprim-sulfamethoxazole.
Figure 1Dendrogram of pulsed-field gel electrophoresis (PFGE) profiles from 50 . A: Isolate origin. A-a, A-b, A-c, A-d, A-e, A-f, A-g, and A-h litters consisted of three (A-a-1 to A-a-3), three (A-b-1 to A-b-3), two (A-c-1 to A-c-2), three (A-d-1 to A-d-3), four (A-e-1 to A-e-4), five (A-f-1 to A-f-5), three (A-g-1 to A-g-3), and two pups (A-h-1 to A-h-2), respectively. Two isolates were obtained per pup. B: Resistance pattern. AMP, ampicillin; DHS, dihydrostreptomycin; GEN, gentamicin; KAN, kanamycin; OTC, oxytetracycline; CHL, chloramphenicol; SXT, trimethoprim-sulfamethoxazole; NAL, nalidixic acid. C: PFGE profile.
Figure 2Dendrogram of pulsed-field gel electrophoresis (PFGE) profiles from 36 . A: Isolate origin. B-a, B-b, B-c, B-d, and B-e litters consisted of two (B-a-1 to B-a-2), four (B-b-1 to B-b-4), five (B-c-1 to B-c-5), three (B-d-1 to B-d-3), and four pups (B-e-1 to B-e-4), respectively. Two isolates were obtained per pup. B: Resistance pattern. AMP, ampicillin; CFZ, cefazolin; CEF, ceftiofur; DHS, dihydrostreptomycin; GEN, gentamicin; OTC, oxytetracycline; CHL, chloramphenicol; SXT, trimethoprim-sulfamethoxazole; NAL, nalidixic acid; ENR, enrofloxacin. C: PFGE profile. Five isolates with the B-2 PFGE profile harboured the SHV-12 ESBL-encoding gene.